| 8377448 |
CD47 related compositions and methods for treating immunological diseases and disorders |
Steven R. Wiley, Ajamete Kaykas, Peter Probst |
2013-02-19 |
|
| 8293500 |
Methods for identifying polypeptide targets and uses thereof for treating immunological diseases |
Steven R. Wiley, Ajamete Kaykas |
2012-10-23 |
|
| 8106201 |
Process for the synthesis of morphinane compounds and intermediates thereof |
Stuart Purcell, Lucy Waddell, Nicholas Hayes, Jarrod Ritchie, Scott Brian Halliday +2 more |
2012-01-31 |
|
| 7875718 |
Process for the synthesis of morphinane compounds and intermediates thereof |
Stuart Purcell, Lucy Waddell, Nicholas Hayes, Jarrod Ritchie, Scott Brian Halliday +2 more |
2011-01-25 |
|
| 7459528 |
Glycoproteins which bind to TNF |
Raymond G. Goodwin, M. Patricia Beckmann |
2008-12-02 |
|
| 7232660 |
CD30 ligand |
Raymond G. Goodwin, Richard J. Armitage |
2007-06-19 |
|
| 7211259 |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
Raymond G. Goodwin |
2007-05-01 |
|
| 7138500 |
Antibodies to human 4-1BB |
Raymond G. Goodwin, Mark Alderson |
2006-11-21 |
|
| 7057022 |
Antibodies which specifically bind to TNF-R |
Raymond G. Goodwin, M. Patricia Beckmann |
2006-06-06 |
|
| 6852486 |
Viral proteins capable of binding LAR |
Raymond G. Goodwin |
2005-02-08 |
|
| 6667039 |
CD30 ligand |
Raymond G. Goodwin, Richard J. Armitage, Hans-Juergen Gruss |
2003-12-23 |
|
| 6572852 |
Method for suppressing inflammatory responses by administering TNFR |
Raymond G. Goodwin, M. Patricia Beckmann |
2003-06-03 |
|
| 6541610 |
Fusion proteins comprising tumor necrosis factor receptor |
— |
2003-04-01 |
|
| 6524298 |
Therapeutic and diagnostic agent delivery |
Keith L. March, Michael Aita, Randy J. Kesten |
2003-02-25 |
$461,000 |
| 6355779 |
Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto |
Raymond G. Goodwin, Mark Alderson |
2002-03-12 |
$274,917,000 |
| 6224584 |
Therapeutic and diagnostic agent delivery |
Keith L. March, Michael Aita, Randy J. Kesten |
2001-05-01 |
|
| 6201105 |
Tumor necrosis factor receptor polypeptides recombinant P75 (Type II) |
Raymond G. Goodwin, M. Patricia Beckmann |
2001-03-13 |
|
| 6143869 |
CD30 ligand oligomers and polypeptides |
Raymond G. Goodwin, Richard J. Armitage, Hans-Juergen Gruss |
2000-11-07 |
$545,859,000 |
| RE36755 |
DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors |
Raymond G. Goodwin, M. Patricia Beckmann |
2000-06-27 |
|
| 5997525 |
Therapeutic and diagnostic agent delivery |
Keith L. March, Michael Aita, Randy J. Kesten |
1999-12-07 |
$4,046,000 |
| 5945397 |
Purified p75 (type II) tumor necrosis factor receptor polypeptides |
Raymond G. Goodwin, M. Patricia Beckmann |
1999-08-31 |
$200,161,000 |
| 5871740 |
Methods of using poxvirus p35 as a chemokine inhibitor and compositions therefore |
— |
1999-02-16 |
$73,624,000 |
| 5840059 |
Therapeutic and diagnostic agent delivery |
Keith L. March, Michael Aita, Randy J. Kesten |
1998-11-24 |
$3,187,000 |
| 5753203 |
CD30 ligand conjugates |
Raymond G. Goodwin, Richard J. Armitage, Hans-Juergen Gruss |
1998-05-19 |
$42,164,000 |
| 5712155 |
DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors |
Raymond G. Goodwin, M. Patricia Beckmann |
1998-01-27 |
$35,144,000 |